Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$4.05 ▼ -0.15
(-3.57%)
MKT CAP: $46.0M • VOL: 4.7K
52W L $4 52W H $9
IMA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $800.0K | $3.5M | $9.2M |
| YoY Revenue Growth % | -77.1% | -61.8% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$48.5M | -$37.0M | -$75.4M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$45.3M | -$36.6M | -$68.2M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$47.8M | -$21.3M | -$79.7M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$47.8M | -$21.3M | -$79.7M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $94.5M | $12.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $133.1M | -$160.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IMA.